Form 8-K - Current report:
SEC Accession No. 0000950170-25-070291
Filing Date
2025-05-13
Accepted
2025-05-13 16:05:11
Documents
15
Period of Report
2025-05-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K olma-20250513.htm   iXBRL 8-K 46895
2 EX-99.1 olma-ex99_1.htm EX-99.1 37042
3 GRAPHIC img39466132_0.jpg GRAPHIC 153631
4 GRAPHIC img39466132_1.jpg GRAPHIC 137618
5 GRAPHIC img39466132_2.jpg GRAPHIC 139225
  Complete submission text file 0000950170-25-070291.txt   798770

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT olma-20250513.xsd EX-101.SCH 24998
17 EXTRACTED XBRL INSTANCE DOCUMENT olma-20250513_htm.xml XML 4749
Mailing Address 780 BRANNAN STREET SAN FRANCISCO CA 94103
Business Address 780 BRANNAN STREET SAN FRANCISCO CA 94103 (415) 651-3316
Olema Pharmaceuticals, Inc. (Filer) CIK: 0001750284 (see all company filings)

EIN.: 300409740 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39712 | Film No.: 25939929
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)